The role of chimerism in organ transplantation

The effect of donor bone marrow cells infusion on chimerism and prognosis of kidney allograft outcomes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106266876N1

Enrollment

Registered

2011-06-27

Start date

2006-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney allograft recipients. Unspecified renal failure

Interventions

Intervention 1: The intervention group: 20 patients who received donor bone marrow cells infusion concurrent with their kidney allograft (DBMI group). triple drug regimen for all patients include cycl

Treatment - Other

The intervention group: 20 patients who received donor bone marrow cells infusion concurrent with their kidney allograft (DBMI group). triple drug regimen for all patients include cyclosporine A (6mg/

The control group: 20 patients who received kidney allograft only. triple drug regimen for all patients include cyclosporine A (6mg/kg/day BD), mycophenolate mofetil (MMF) (2 gr/day BD) and prednisolo

Eligibility

Sex/Gender

All

Age

25 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Being the case of first renal transplantion Exclusion criteria: Previous transfusion; retransplantation; cardiovascular diseases; having genetic diseases and morbid obesity.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum creatinine levels. Timepoint: Weekly in first 3 month and then monthly during two years follow-up. Method of measurement: Colorimetric method (Jaffe).;Microchimerism quantification. Timepoint: Weeks: 1 and 2; months: 1, 3, 6 and 12. Method of measurement: Real-time PCR.;Acute rejection episodes. Timepoint: During 6 months after transplantation. Method of measurement: Clinical evaluation and biopsy protocol.	—

Measure

Time frame

Serum creatinine levels. Timepoint: Weekly in first 3 month and then monthly during two years follow-up. Method of measurement: Colorimetric method (Jaffe).;Microchimerism quantification. Timepoint: Weeks: 1 and 2; months: 1, 3, 6 and 12. Method of measurement: Real-time PCR.;Acute rejection episodes. Timepoint: During 6 months after transplantation. Method of measurement: Clinical evaluation and biopsy protocol.

—

Secondary

Measure	Time frame
SCD30. Timepoint: Days: 4, 14 and 30 after transplant. Method of measurement: ELISA method.;Anti-HLA antibodies. Timepoint: Second week; months: 1 and 3. Method of measurement: ELISA method.;Sera cytokines (IL-10 and IFN-g). Timepoint: Days: 10 and 14 after transplant. Method of measurement: ELISA method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ghasem Solgi

Immunology dept, School of medicine, AJUMS, Ahvaz, Iran

solgi@razi.tums.ac.ir ghsolgi2@yahoo.com+98 61 1374 8747

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026